JP2002515035A - アミノステロール化合物の治療学的使用 - Google Patents
アミノステロール化合物の治療学的使用Info
- Publication number
- JP2002515035A JP2002515035A JP54260297A JP54260297A JP2002515035A JP 2002515035 A JP2002515035 A JP 2002515035A JP 54260297 A JP54260297 A JP 54260297A JP 54260297 A JP54260297 A JP 54260297A JP 2002515035 A JP2002515035 A JP 2002515035A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- mice
- disease
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.薬剤的に許容しうるキャリアーもしくは賦形剤および以下の式: に係る化合物もしくは薬剤的に許容しうるその塩を含有する組成物を有効量投与 することを含む、単純疱疹ウィルス感染、炎症、関節炎、および癌からなる群か ら選択される疾病もしくは慢性疾患(disease or ailment)を治療するための方 法。 2.疾病もしくは慢性疾患が炎症である、請求項1記載の方法。 3.疾病もしくは慢性疾患が関節炎である、請求項1記載の方法。 4.疾病もしくは慢性疾患が癌である、請求項1記載の方法。 5.癌が黒色腫である、請求項4記載の方法。 6.癌が白血病である、請求項4記載の方法。 7.白血病が急性リンパ球性白血病である、請求項6記載の方法。 8.白血病が急性骨髄性白血病である、請求項6記載の方法。 9.疾病もしくは慢性疾患が単純疱疹ウィルス感染である、請求項1記載の方 法。 10.薬剤的に許容しうるキャリアーもしくは賦形剤および以下の式: に係る化合物もしくは薬剤的に許容しうるその塩を含有する組成物を有効量投与 することを含む、哺乳動物における食欲を抑制する方法。 11.薬剤的に許容しうるキャリアーもしくは賦形剤および以下の式:に係る化合物もしくは薬剤的に許容しうるその塩を含有する組成物を有効量投与 することを含む、哺乳動物における増殖因子の生成を阻害する方法。 12.薬剤的に許容しうるキャリアーもしくは賦形剤および以下の式: に係る化合物もしくは薬剤的に許容しうるその塩を含有する組成物を有効量投与 することを含む、哺乳動物における体重増加を阻害する方法。 13.薬剤的に許容しうるキャリアーもしくは賦形剤および以下の式: に係る化合物もしくは薬剤的に許容しうるその塩を含有する組成物を有効量投与 することを含む、哺乳動物における利尿をもたらす方法。 14.利尿効果が鬱血性心不全の治療に有用である、請求項13記載の方法。 15.利尿効果がネフローゼ症候群の治療に有用である、請求項13記載の方 法。 16.利尿効果が肝硬変の治療に有用である、請求項13記載の方法。 17.利尿効果が頭部損傷から派生する脳水腫の治療に有用である、請求項1 3記載の方法。 18.利尿効果がリンパ水腫の治療に有用である、請求項13記載の方法。 19.利尿効果が術後の多血症の治療に有用である、請求項13記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1762796P | 1996-05-17 | 1996-05-17 | |
US2954196P | 1996-11-01 | 1996-11-01 | |
US60/017,627 | 1996-11-01 | ||
US60/029,541 | 1996-11-01 | ||
PCT/US1997/008395 WO1997044044A1 (en) | 1996-05-17 | 1997-05-16 | Therapeutic uses for an aminosterol compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002515035A true JP2002515035A (ja) | 2002-05-21 |
JP2002515035A5 JP2002515035A5 (ja) | 2005-01-13 |
Family
ID=26690120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54260297A Pending JP2002515035A (ja) | 1996-05-17 | 1997-05-16 | アミノステロール化合物の治療学的使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090105204A1 (ja) |
EP (1) | EP0923377A1 (ja) |
JP (1) | JP2002515035A (ja) |
AU (1) | AU726909B2 (ja) |
CA (1) | CA2255856C (ja) |
WO (1) | WO1997044044A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007532625A (ja) * | 2004-04-13 | 2007-11-15 | セファロン インコーポレイティド | チオ置換アリールメタンスルフィニル誘導体 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
WO1998019682A1 (en) * | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
FR2981351A1 (fr) | 2011-10-17 | 2013-04-19 | Univ Nice Sophia Antipolis | Derives aminosteroidiens anti-diabetiques |
EP2934543B1 (en) * | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
WO2019227176A1 (en) * | 2018-06-01 | 2019-12-05 | Monash University | Methods of activating cells via ptp 1b inhibition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11506775A (ja) * | 1995-06-07 | 1999-06-15 | マガイニン ファーマシューティカルズ インク. | 医薬品の製造のためのスクアラミンの使用 |
JP2002515019A (ja) * | 1995-06-07 | 2002-05-21 | マガイニン ファーマシューティカルズ インク. | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2735002B1 (fr) * | 1995-06-07 | 1997-07-25 | Ampafrance | Siege pour enfant a assise moulee |
US5840936A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US5763430A (en) * | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
US5795885A (en) * | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
-
1997
- 1997-05-16 EP EP97926574A patent/EP0923377A1/en not_active Withdrawn
- 1997-05-16 AU AU31306/97A patent/AU726909B2/en not_active Ceased
- 1997-05-16 CA CA002255856A patent/CA2255856C/en not_active Expired - Fee Related
- 1997-05-16 WO PCT/US1997/008395 patent/WO1997044044A1/en not_active Application Discontinuation
- 1997-05-16 JP JP54260297A patent/JP2002515035A/ja active Pending
-
2008
- 2008-10-20 US US12/254,656 patent/US20090105204A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11506775A (ja) * | 1995-06-07 | 1999-06-15 | マガイニン ファーマシューティカルズ インク. | 医薬品の製造のためのスクアラミンの使用 |
JP2002515019A (ja) * | 1995-06-07 | 2002-05-21 | マガイニン ファーマシューティカルズ インク. | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007532625A (ja) * | 2004-04-13 | 2007-11-15 | セファロン インコーポレイティド | チオ置換アリールメタンスルフィニル誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP0923377A1 (en) | 1999-06-23 |
CA2255856C (en) | 2008-05-13 |
AU3130697A (en) | 1997-12-09 |
CA2255856A1 (en) | 1997-11-27 |
WO1997044044A1 (en) | 1997-11-27 |
US20090105204A1 (en) | 2009-04-23 |
AU726909B2 (en) | 2000-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6143738A (en) | Therapeutic uses for an aminosterol compound | |
Mahmoud et al. | Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma | |
EP1484059B1 (en) | Antiviral compositions comprising phenylacetic acid derivatives | |
AU768307B2 (en) | Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis | |
WO1992019249A1 (en) | Compositions for the prevention and/or treatment of pathological processes | |
US4916117A (en) | Treatment of inflammation using alpha 1-antichymotrypsin | |
US6534534B1 (en) | Pharmaceutical composition active in reducing production of MCP-1 protein | |
CN114504578A (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
JP2002515035A (ja) | アミノステロール化合物の治療学的使用 | |
US20080221075A1 (en) | Therapeutic Uses For Aminosterol Compounds | |
CN101654393A (zh) | 作为肝脏保护剂的化合物和组合物 | |
KR20050106038A (ko) | 심장질환 및 신장질환의 치료를 위한 아데노신 a1 수용체길항제 | |
PL186377B1 (pl) | Kompozycja farmaceutyczna do leczenia chorób autoimmunologicznych | |
Wong et al. | Comparative effects of tetrandrine and berbamine on acute and relapsing experimental allergic encephalitis in Lewis rats | |
JP4580479B2 (ja) | 抗hiv感染症剤 | |
JP2000136139A (ja) | 有機ゲルマニウム化合物を有効成分とするmcp−1受容体拮抗剤、及びmcp−1が関与する炎症性疾患及び臓器障害の発症予防または治療剤 | |
CN110891580A (zh) | 使用三氧化二砷治疗多发性硬化症的方法 | |
JP2001523724A (ja) | 運動ニューロン病および脱髄病を治療するためのシチコリン | |
CN112972462B (zh) | 帕比司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用 | |
CN112972448B (zh) | 贝利司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用 | |
CN115501236B (zh) | 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用 | |
RU2825318C2 (ru) | Применение экстракта ладанника в качестве гепатопротекторного средства для терапевтического лечения болезней печени | |
JP2000506839A (ja) | 天然ヒトα―インターフェロンを含む薬剤組成物 | |
WO2023165479A1 (zh) | 硝酮化合物或其在药学上可接受的盐与sglt-2抑制剂联合应用 | |
US5955446A (en) | Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20080415 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080627 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080903 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081010 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090106 |